ReachRxResearch
Home
Research
Sign Up
Alzheimer’s disease target and drug discovery by leveraging multiomics and electronic health data
Back to Research Hub
  1. Home
  2. Research Hub
  3. Alzheimer’s disease target and drug disc…

Alzheimer’s disease target and drug discovery by leveraging multiomics and electronic health data

Nature Neuroscience·October 8Open Access
NeurosciencesPractice changingAlzheimer'S DiseaseMild Cognitive ImpairmentMendelian Randomization Study With Functional Validation And Pharmacoepidemiological Cohort StudyAntidepressantGABA-B AgonistSoluble Epoxide Hydrolase InhibitorOlder AdultEC5026BaclofenTrazodone

Summary

View source

What was studied

Mendelian randomization (MR) applied to multiple AD GWAS and functional multiomics datasets was used to nominate druggable targets, with functional validation of EPHX2 inhibition in iPSC-derived neurons, cerebral organoids, and a 5xFAD mouse model; separately, electronic health records from 111,680 MCI patients were screened for drugs associated with reduced AD incidence.

Key findings

19 druggable targets were identified for European ancestry and 7 for African ancestry; the EPHX2 protective missense variant p.Arg287Gln reduced EPHX2 protein and pTau-181 levels in AD patient iPSC-derived neurons; pharmacological EPHX2 inhibition improved cognition in 5xFAD mice; among MCI patients (23.7% developed AD), 12 drugs were associated with reduced AD incidence, including trazodone (targeting ADRA1A) and baclofen (targeting GABBR1).

Study limitations

The alzMR score inflation assumption (≥1% heritability explained by MR instruments) may not hold for ~4–8% of genes with low instrument strength. MR estimates reflect total causal effects only, and compensatory SNP interactions or opposing causal pathways could bias results. The pharmacoepidemiology analysis used observational insurance claims data, so residual confounding cannot be excluded despite propensity score matching.

Clinical implications

EPHX2 inhibition is a promising therapeutic direction for AD, supported by genetic, cellular, organoid, and mouse model evidence. Trazodone and baclofen, both already in clinical use, warrant prospective study as potential agents to slow AD progression in MCI patients.

Caveats

  • Drug associations identified via electronic health records are hypothesis-generating; confounding by indication and channeling bias are inherent risks even after propensity score matching
  • The EPHX2 mouse model used is 5xFAD, which has high amyloid overexpression and may not fully represent the complexity of human AD; cognitive benefit in mice does not guarantee clinical efficacy
  • The pharmacoepidemiology cohort (Optum CDM) is limited to commercially insured US individuals and Medicare Advantage beneficiaries, which may limit generalizability to uninsured or non-US populations

Related Questions

Explore related topics

What is the evidence for EPHX2 inhibitors in Alzheimer's disease treatment?Are trazodone or baclofen associated with reduced dementia risk in observational studies?How is Mendelian randomization used to identify drug targets for neurodegenerative diseases?

Publication Details

Year
2026
Journal
Nature Neuroscience
Sample Size
n=111,680
Source
View article
Keep scrolling
More content below.
Up Next